Key clinical point: For patients with metastatic, treatment-naive clear cell renal cell carcinoma, an alternate (2 weeks on, 1 week off) sunitinib schedule may be more tolerable than the FDA-approved 4:2 schedule.

Major finding: After a median follow-up of 17 months, 25% of patients had grade 3 fatigue, hand-foot syndrome, or diarrhea, 37% needed dose reductions, and 10% stopped treatment because of toxicities.

Study details: Single-arm, multicenter phase 2 study of 59 patients initiating oral sunitinib (50 mg daily) on a 2:1 schedule.

Disclosures: Pfizer makes sunitinib and funded the study. Dr. Jonasch disclosed research funding, travel reimbursement, and an advisory relationship with Pfizer.

Read the article.